https://wellcomecollection.org/concepts/bc3mz58j
Find books, manuscripts, paintings, illustrations, photos and unpublished archives about Hoffmann-La Roche, many of them with free online access.
hoffmann la rochewellcome collection
https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastric-cancer-likelihood-of-approval/
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer.
hoffmann la rochegastric canceratezolizumablikelihood
https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-paraganglioma-glomus-jugulare-tumor-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-304651&utm_campaign=recommended-articles-pi
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Paraganglioma (Glomus Jugulare Tumor).
hoffmann la rocheglomus jugulareatezolizumabparaganglioma
https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-chondrosarcoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-274108&utm_campaign=recommended-articles-pi
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Chondrosarcoma.
hoffmann la rocheatezolizumabchondrosarcomalikelihood
https://www.pharmaceutical-technology.com/data-insights/ocrelizumab-f-hoffmann-la-roche-autoimmune-encephalitis-post-infectious-likelihood-of-approval/
Ocrelizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Autoimmune Encephalitis (Post-Infectious).
hoffmann la rocheautoimmune encephalitisocrelizumabpost
https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-192020&utm_campaign=recommended-articles-pi
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma.
hoffmann la rochevemurafenibneuroblastomalikelihood
https://www.sap.com/documents/2025/03/7222ba3f-fc7e-0010-bca6-c68f7e60039b.html
F. Hoffmann-La Roche Ltd developed the TEMPER web portal to integrate data from various sources, including third-party devices and our warehouse management...
hoffmann la rochesap innovationltdawards
https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-sarcomas-likelihood-of-approval-2/
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas.
hoffmann la rochevemurafenibsarcomaslikelihood
https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/
Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL).
hoffmann la rochechronic lymphocyticobinutuzumabrefractory
https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastric-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-184297&utm_campaign=recommended-articles-pi
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Gastric Cancer.
hoffmann la rochegastric canceratezolizumablikelihood
https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-inflammatory-myofibroblastic-tumor-imt-likelihood-of-approval/
Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT).
hoffmann la rochealectinibinflammatorytumor
https://informaconnect.com/bpieurope/speakers/katharina-bruno-thakur/
Go beyond theory at BioProcess International Europe. Master the future of biomanufacturing: from cell line development, upstream, downstream, ATMPs to...
hoffmann la rochekatharinabrunothakurbioprocess
https://www.pharmaceutical-technology.com/data-insights/ensomafusp-alfa-f-hoffmann-la-roche-follicular-lymphoma-likelihood-of-approval/
Ensomafusp alfa is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Follicular Lymphoma.
hoffmann la rochefollicular lymphomaalfa
https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-craniopharyngioma-likelihood-of-approval-2/
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma.
hoffmann la rochevemurafenibcraniopharyngiomalikelihood
https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-graft-versus-host-disease-gvhd-likelihood-of-approval/
Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Graft Versus Host Disease (GVHD).
hoffmann la rochegraft versus hostobinutuzumab
https://www.pharmaceutical-technology.com/data-insights/faricimab-f-hoffmann-la-roche-non-proliferative-diabetic-retinopathy-npdr-likelihood-of-approval/
Faricimab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).
hoffmann la rochefaricimabnonproliferativediabetic